Disseminated Intravascular Coagulation (DIC)MANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

638 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp65

Immediate priorities

›Hemorrhagic emergency triggers

›Profuse bleeding from multiple sites

›IV lines, wound sites, mucosal surfaces simultaneously

›Activate massive transfusion protocol immediately

›Purpura fulminans

›Symmetric rapidly progressive purpuric skin lesions

›High mortality — treat underlying cause emergently

›Hemodynamic shock

›SBP < 90 mmHg or MAP < 65 mmHg

›Large-bore IV access x2 and arterial line

›ABCs and resuscitation

›Airway protection

›GCS < 8 or inability to protect airway — proceed to intubation

›Oropharyngeal hemorrhage increases aspiration risk

›Breathing support

›SpO2 target >= 94% with supplemental oxygen

›ARDS pattern possible from microvascular pulmonary thrombosis

›Circulation restoration

›IV crystalloid for initial volume resuscitation

›Vasopressors (norepinephrine) for persistent shock after fluids

Monitoring and targets

›Hemodynamic monitoring

›Continuous cardiac monitoring

›Arrhythmias from electrolyte derangements

›Right heart strain pattern if concurrent PE suspected

›Arterial line placement

›Continuous blood pressure monitoring

›Repeated arterial blood gas sampling

›Urinary catheter

›Urine output target >= 0.5 mL/kg/hour

›Oliguria indicates renal microvascular thrombosis

›Serial coagulation monitoring

›Initial ISTH DIC score, repeat every 6 to 8 hours

›Score >= 5 defines overt DIC

›Score trending up indicates decompensation

›Platelet count, PT, fibrinogen trend

›Rapidly falling platelet count signals active consumption

›Fibrinogen < 1.5 g/L triggers cryoprecipitate

Critical decision points

›Identify and treat the underlying cause — single most important intervention

›Sepsis: antibiotics within 1 hour and source control

›Most common DIC trigger in ICU (44% pooled mortality)

›Obstetric emergency: delivery for abruption, HELLP, amniotic fluid embolism

›Coordinate with OB/MFM immediately

›Malignancy: ATRA plus arsenic trioxide for APL

›APL is the most treatable malignancy-associated DIC

›Trauma: damage control surgery and resuscitation

›Distinguish from trauma-induced coagulopathy — TXA indicated early in trauma

›Phenotype determination

›Hemorrhagic phenotype: consumptive bleeding dominant

›Blood product replacement is primary strategy

›Thrombotic phenotype: digital ischemia, purpura fulminans

›Therapeutic heparin when thrombosis predominates

›Escalation triggers

›Hematology consult for refractory coagulopathy or malignancy-associated DIC

›ICU admission for all overt DIC — continuous monitoring required

›Step-down unit acceptable for early-phase/compensated DIC

PITFALLS

›Diagnostic and management pitfalls

›Fibrinogen as a false-negative in early DIC

›Fibrinogen is an acute-phase reactant — may be normal or elevated in sepsis despite active DIC

›Serial trending is more informative than a single value

›Antifibrinolytics contraindicated in standard DIC

›TXA appropriate only in hyperfibrinolytic states (APL, early trauma)

›Administering TXA in thrombotic DIC worsens organ injury

›Missing early-phase DIC

›SIC score detects compensated DIC before ISTH score reaches 5

›Approximately 60% of sepsis patients meet SIC criteria; most progress to overt DIC if untreated

02History/hx61

Presenting symptoms

›Bleeding manifestations

›Mucosal bleeding

›Gingival oozing

›Epistaxis

›Skin bleeding

›Petechiae

›Ecchymoses

›Wound and IV site oozing

›Internal bleeding

›Hematuria

›GI bleeding — hematemesis or melena

›Hemoptysis

›Organ dysfunction symptoms

›Neurologic

›Altered mental status from microvascular thrombosis

›Focal deficits if large vessel involvement

›Renal

›Oliguria or anuria

›Hematuria

›Pulmonary

›Dyspnea from ARDS or pulmonary hemorrhage

Trigger identification

›Sepsis context

›Fever, rigors, hypotension

›Most common DIC trigger in ICU

›Gram-positive and gram-negative bacteremia, fungemia, viral hemorrhagic fevers

›Source of infection

03Physical Exam/exam48

Vital signs

›Hemodynamic stability assessment

›Blood pressure

›SBP < 90 mmHg or MAP < 65 mmHg indicates shock

›Reported as hemodynamic instability in 63% of DIC presentations

›Heart rate

›Tachycardia from hemorrhage or sepsis

›Temperature

›Fever — sepsis trigger

›Hypothermia — severe sepsis pattern

›Respiratory rate

›Tachypnea from ARDS or acidosis

Skin and mucous membranes

›Bleeding and skin lesions

›Petechiae

›Thrombocytopenia marker — pinpoint non-blanching lesions

›Palatal petechiae, lower extremity distribution common

›Purpura and ecchymoses

›Spontaneous or pressure-site ecchymoses

›Purpura fulminans — symmetric rapidly progressive necrotic purpura

›Classically associated with meningococcemia

›Acral cyanosis

›Thrombotic phenotype — peripheral microvascular occlusion

›Digital ischemia or gangrene in severe cases

›Active bleeding sites

›IV site and wound oozing

›Bleeding from multiple puncture sites simultaneously is pathognomonic

›Mucous membranes

04Differential Diagnosis/ddx33

Life-threatening mimics

›Thrombotic microangiopathies

›Thrombotic thrombocytopenic purpura (TTP)

›ICD-10 M31.1

›Thrombocytopenia plus MAHA; PT/aPTT typically normal

›ADAMTS13 activity < 10% is diagnostic

›Hemolytic uremic syndrome (HUS)

›ICD-10 D59.3

›Thrombocytopenia plus MAHA plus renal failure

›Coagulation tests usually normal — key differentiator from DIC

›Heparin-induced thrombocytopenia (HIT)

›ICD-10 D75.82

›Platelet drop 5 to 10 days post-heparin exposure

›Thrombosis predominates; 4Ts score and anti-PF4 antibodies distinguish

Coagulopathy mimics

›Severe liver disease

›ICD-10 K72.91

›Prolonged PT, low fibrinogen, thrombocytopenia — overlaps significantly with DIC

›D-dimer elevation less dramatic; clinical context differs

›Factor VIII level helps distinguish — low in DIC, preserved or elevated in liver disease

›Massive transfusion and dilutional coagulopathy

›History of > 10 units pRBCs

›Antifibrinolytics are appropriate here, unlike standard DIC

›Primary fibrinolysis

›Rare; low fibrinogen and elevated FDPs but platelet count normal or near-normal

›Associated with prostate cancer, some liver conditions

Trauma-related coagulopathy

›Trauma-induced coagulopathy (TIC)

05Laboratory Tests/lt48

Core coagulation panel

›ISTH DIC scoring labs

›Platelet count

›< 50 x 10^9/L scores 2 points; < 100 x 10^9/L scores 1 point

›Serial decline is key — single value may not reflect consumption rate

›PT/INR

›> 6 seconds prolonged scores 2 points; > 3 seconds scores 1 point

›aPTT prolonged (supportive but not included in ISTH score)

›D-dimer / fibrin degradation products

›> 7x ULN scores 3 points per 2025 ISTH criteria

›> 3x ULN scores 2 points

›Normal D-dimer effectively excludes DIC

›Fibrinogen

›< 1 g/L scores 1 point in ISTH scoring

›May be falsely normal or elevated as acute-phase reactant in sepsis

›Target fibrinogen > 1.5 g/L for replacement threshold

Additional hematology labs

›Hemolysis assessment

›Peripheral blood smear

›Schistocytes indicate microangiopathic hemolytic anemia

›Present in both DIC and TTP — quantify burden to differentiate

›LDH

›Elevated in hemolysis and tissue injury

›Haptoglobin

›Reduced in intravascular hemolysis

›Reticulocyte count

›Compensatory reticulocytosis in active hemolysis

›ADAMTS13 activity

06Diagnostic Tests/dt72

Scoring Systems

›ISTH Overt DIC Score

›Scoring components

›Platelet count: < 100 = 1 point; < 50 = 2 points

›D-dimer/FDP: > 3x ULN = 2 points; > 7x ULN = 3 points (2025 update)

›PT prolongation: > 3 seconds = 1 point; > 6 seconds = 2 points

›Fibrinogen: < 1 g/L = 1 point

›Interpretation

›Score >= 5 = overt DIC (compatible with diagnosis, treat)

›Score < 5 = non-overt DIC (repeat daily; treat underlying cause)

›Sensitivity 91%, specificity 97% for overt DIC diagnosis

›Sepsis-Induced Coagulopathy (SIC) Score

›Scoring components

›PT-INR: 1.2-1.4 = 1 point; >= 1.4 = 2 points

›Platelet count: 100-150 = 1 point; < 100 = 2 points

›SOFA score: 1 point per SOFA point up to 2

›Interpretation

›Score >= 4 = SIC (early/compensated DIC); anticoagulation recommended

›Approximately 60% of sepsis patients meet SIC criteria

›Nearly all SIC patients progress to overt DIC without treatment

›Quick DIC Score

›Formula: PT-INR x D-dimer / platelet count

›Simplified index for rapid bedside calculation

›High diagnostic accuracy in validation studies

›Proposed as faster alternative to ISTH score when full labs pending

›Viscoelastic Testing (TEG/ROTEM)

›Point-of-care assessment of clot formation, strength, fibrinolysis

›Results available in 5 to 10 minutes

›Particularly useful in obstetric and trauma DIC for guiding transfusion

›Key parameters

›Clot formation time (CFT/K-time) — prolonged in coagulation factor deficiency

›Maximum clot firmness (MCF/MA) — reduced in thrombocytopenia and hypofibrinogenemia

›Lysis index — elevated in hyperfibrinolytic states

MRI

›MRI indications in DIC

›Brain MRI with DWI for neurologic deficits

›Identifies microvascular thrombotic infarcts

›Intracranial hemorrhage evaluation when CT inconclusive

›MRI brain not first-line in acute hemodynamic instability

›CT head preferred for rapid initial evaluation

›Spinal MRI for focal cord signs

›Epidural hematoma from coagulopathy

›Cord infarction from microvascular thrombosis

›CT head

›Indication: new or worsening neurologic symptoms

›Intracranial hemorrhage from coagulopathy

›Ischemic stroke from cerebral microvascular thrombosis

›Obtain without contrast first for hemorrhage evaluation

›CT chest

›Indication: respiratory failure or hemoptysis

›ARDS pattern — bilateral ground-glass opacities

›Pulmonary hemorrhage from consumptive thrombocytopenia

›CT pulmonary angiography if PE suspected as concurrent diagnosis

›CT abdomen and pelvis

›Indication: identify intra-abdominal septic source or malignancy

›Abscess, perforated viscus, ischemic bowel

›Retroperitoneal hematoma from coagulopathy

›IV contrast with caution in acute renal injury

Ultrasound

›Point-of-care ultrasound (POCUS)

›Cardiac POCUS

›LV and RV function assessment

›Right heart strain pattern if concurrent PE

›Pericardial effusion in inflammatory conditions triggering DIC

›IVC assessment

›Volume responsiveness estimation

›IVC collapsibility index for fluid resuscitation guidance

›Obstetric ultrasound

›Indication: suspected placental abruption or retained products

›Retroplacental hematoma in abruption

›Retained products of conception after delivery

›Fetal heart rate monitoring concurrent with DIC management

›Abdominal ultrasound

›Hepatosplenomegaly from underlying malignancy

›Free fluid from hemorrhage or ascites

07Disposition/dispo38

ICU admission

›Overt DIC (ISTH score >= 5) — all require ICU admission

›Continuous hemodynamic monitoring

›Arterial line for blood pressure and serial ABGs

›Central venous access for vasopressors if required

›Serial coagulation labs every 6 to 8 hours initially

›Multidisciplinary care

›Hematology for complex or malignancy-associated DIC

›Critical care medicine

›Early-phase or compensated DIC (SIC score >= 4)

›ICU or step-down unit with close monitoring

›Hourly hemodynamic reassessment

›Repeat ISTH DIC score within 6 hours

Consult triggers

›Specialist consultation indications

›Hematology

›Diagnostic uncertainty between DIC and TTP or HIT

›Refractory coagulopathy not responding to blood products

›Malignancy-associated DIC management

›Surgery or obstetrics and gynecology

›Obstetric emergencies requiring delivery

›Intra-abdominal source requiring surgical control

›Transfusion medicine

›Massive transfusion protocol activation

›Irradiated or leukodepleted product requirements

Transfer criteria

›Transfer to higher level of care

›Facilities without ICU capability

08Treatment/t69

Treat the underlying cause

›Sepsis management

›Broad-spectrum antibiotics within 1 hour of recognition

›Piperacillin-tazobactam 4.5 g IV every 6 hours or

›Meropenem 1 g IV every 8 hours for resistant organisms

›Vancomycin 25 to 30 mg/kg IV loading dose for MRSA coverage

›Source control

›Abscess drainage

›Line removal if catheter-related bacteremia

›Obstetric causes

›Placental abruption or HELLP — expedite delivery

›Coordinate with OB/MFM urgently

›Amniotic fluid embolism — supportive resuscitation and delivery

›Malignancy-associated DIC

›APL: ATRA 45 mg/m2/day in 2 divided doses

›Plus arsenic trioxide 0.15 mg/kg/day IV

›Most effective intervention for APL-associated hyperfibrinolytic DIC

Blood product replacement

›Platelet transfusion

›Target platelet count > 50 x 10^9/L if actively bleeding

›1 adult dose (1 apheresis unit or pool of 4-6 random donor)

›Recheck platelet count 1 hour post-transfusion

›Target > 20 x 10^9/L if not actively bleeding

›Prophylactic threshold for critically ill DIC patients

›Fresh frozen plasma (FFP)

›Indication: PT or aPTT > 1.5x normal with active bleeding or planned procedure

›Dose: 15 to 25 mL/kg IV

›Contains all coagulation factors and natural anticoagulants

›Volume overload risk in patients with cardiac or renal dysfunction

›Consider prothrombin complex concentrate (PCC) as alternative

›Cryoprecipitate

›Indication: fibrinogen < 1.5 g/L

›Dose: 10 units IV (each unit is approximately 15 to 20 mL)

›Each pool raises fibrinogen by approximately 0.5 to 1 g/L

›Rich in fibrinogen, factor VIII, von Willebrand factor, factor XIII

›Packed red blood cells

›Transfusion threshold hemoglobin < 70 g/L (restrictive strategy)

›Higher threshold hemoglobin < 80 g/L if cardiac disease

›Irradiated and leukodepleted products preferred in immunocompromised

›Fibrinogen concentrate (alternative to cryoprecipitate)

›3 to 4 g IV when fibrinogen < 1.5 g/L

›Faster preparation and more consistent dosing than cryoprecipitate

›Preferred in many European centers

Anticoagulation

›VTE prophylaxis in non-bleeding DIC

›LMWH recommended even with DIC when not actively bleeding

›Enoxaparin 40 mg SC daily (renally dose-adjusted)

›Hold if platelets < 30 x 10^9/L or active bleeding

›UFH 5000 units SC twice or three times daily as alternative

›Preferred if rapid reversal may be needed

›Therapeutic anticoagulation for thrombotic DIC

›Indication: digital ischemia, purpura fulminans, large vessel thrombosis

›UFH infusion titrated to aPTT 60 to 80 seconds

›Or LMWH at therapeutic dose with anti-Xa monitoring

›Weigh hemorrhagic risk carefully before initiating

›Antithrombin concentrate

›Levels < 47% associated with > 40% 28-day mortality in sepsis-DIC

›May be considered in sepsis-associated DIC with low antithrombin

›No robust RCT mortality benefit demonstrated to date

›Dose: target antithrombin activity > 80%

›Recombinant thrombomodulin

›Under investigation for sepsis-associated DIC

›Some evidence for improved ISTH DIC score normalization

›Not yet standard of care; no proven mortality benefit in RCTs

Medications to avoid

›Antifibrinolytics (tranexamic acid)

›Generally contraindicated in DIC — worsens microvascular thrombosis

›Exception: markedly hyperfibrinolytic states (APL, early trauma with fibrinolysis)

›Viscoelastic testing can confirm hyperfibrinolytic pattern before use

›Activated protein C (drotrecogin alfa)

›Withdrawn from market — no mortality benefit and increased bleeding

›Long-acting antiplatelet agents

›Discontinue unless strongly indicated (e.g., recent PCI within 30 days)

09Special Populations/sp65

Pregnancy

›Obstetric causes of DIC

›Placental abruption

›Sudden onset abdominal pain and vaginal bleeding

›Concealed hemorrhage possible — fetal distress may precede maternal symptoms

›Immediate delivery is definitive treatment

›Amniotic fluid embolism

›Sudden cardiovascular collapse during labor or delivery

›Profound DIC and ARDS develop rapidly

›Supportive resuscitation and emergency cesarean section

›HELLP syndrome

›Hemolysis, elevated liver enzymes, low platelets

›Fibrinogen may be preserved early — trend closely

›Magnesium sulfate for seizure prophylaxis; delivery is curative

›Septic abortion

›Broad-spectrum antibiotics and uterine evacuation

›Blood product considerations in pregnancy

›Fibrinogen requirements higher in pregnancy

›Normal pregnancy fibrinogen 3.5 to 6.5 g/L — lower levels indicate significant DIC

›Cryoprecipitate or fibrinogen concentrate target > 2 g/L in obstetric DIC

›Platelet transfusion threshold same as non-pregnant patients

›Cell salvage acceptable in obstetric hemorrhage with leukocyte depletion filter

›Fetal considerations

›Fetal monitoring concurrent with maternal resuscitation

›Fetal distress may indicate placental compromise before maternal hemodynamic instability

›Expedite delivery once maternal stabilization permits

Geriatric

›Physiologic vulnerability

10Background/b75

Epidemiology

›Incidence and prevalence

›DIC occurs in 1% of hospitalized patients

›Accounts for significant ICU morbidity and mortality worldwide

›Most common in sepsis

›Complicates 30 to 50% of severe sepsis cases

›ICU incidence approximately 25 to 35% in septic patients

›Obstetric DIC

›Complicates 0.03 to 0.35% of deliveries

›Placental abruption most common obstetric trigger

›Mortality

›Pooled 28-day mortality in sepsis-associated DIC approximately 44% by ISTH criteria

›SOFA score >= 12 predicts > 40% mortality

›Antithrombin activity < 47% is independent mortality predictor

›DIC resolution by day 3 to 6 associated with significantly improved survival

›APL-associated DIC: mortality dramatically reduced with ATRA plus arsenic trioxide

›Classification by cause

›Infection/sepsis: 35 to 43% of DIC cases

›Malignancy: 24 to 34%

›Obstetric complications: 4 to 12%

›Trauma: 4 to 12%

›Vascular abnormalities and toxins: remaining cases

Pathophysiology

›Core mechanism

›Simultaneous systemic coagulation activation and consumptive coagulopathy

›Microvascular thrombosis causing organ dysfunction

›Consumption of platelets, fibrinogen, and coagulation factors causing bleeding

›Tissue factor pathway predominant trigger

›Tissue factor expressed on monocytes/macrophages in response to endotoxin and cytokines

›Leads to thrombin generation and fibrin deposition

›Natural anticoagulant depletion

›Protein C, antithrombin, TFPI levels fall as DIC progresses

›Loss of natural brakes amplifies thrombosis

›Phenotypic spectrum

›Hemorrhagic phenotype

›Fibrinolysis activation concurrent with coagulation

›Consumptive thrombocytopenia and coagulation factor depletion

›Classic presentation: bleeding from multiple sites

›Thrombotic phenotype

›Fibrinolysis suppressed by PAI-1 upregulation

›Microvascular thrombosis without significant bleeding

›Classic presentation: organ failure, digital ischemia

›2025 ISTH phase classification

›Pre-DIC: subclinical activation, no clinical or lab criteria yet

›Early-phase (compensated) DIC: SIC criteria met; detectable but compensated

›Overt DIC: ISTH score >= 5; uncompensated consumption with clinical manifestations

›Immune mechanisms

›Neutrophil extracellular traps (NETs) promote thrombin generation

›Major link between infection and DIC

›Complement activation amplifies coagulation

›Endothelial damage from cytokines disrupts normal anticoagulant surface

Therapeutic Considerations

›Evidence base for blood product replacement

›FFP for coagulation factor replacement

›Class IIa recommendation for active bleeding with prolonged PT/aPTT > 1.5x normal

›Limited RCT data; recommended by ISTH, BCSH, and JSTH harmonized guidelines

›Cryoprecipitate for fibrinogen replacement

›Fibrinogen < 1.5 g/L is the accepted threshold

›Fibrinogen concentrate is equivalent with more consistent dosing

›Platelet transfusion threshold evidence

›> 50 x 10^9/L for bleeding supported by international consensus

›No level I evidence for specific threshold; based on expert consensus

›Anticoagulation evidence

›LMWH for VTE prophylaxis in non-bleeding DIC

›Supported by ISTH SSC guidance (Class IIa)

›Observational data suggests survival benefit in sepsis-DIC

›Therapeutic heparin for thrombotic DIC

›Expert consensus recommendation; no RCT evidence

›Antithrombin concentrates

›Japanese guidelines recommend in sepsis-DIC

›ISTH and European guidelines more cautious — insufficient RCT mortality data

›Investigational and adjunctive therapies

›Recombinant thrombomodulin

›Phase III trials showed improved DIC score but no mortality reduction

›May be considered in sepsis-DIC at specialized centers

›Antifibrinolytics — contraindicated except hyperfibrinolytic DIC

›TEG/ROTEM confirmation of fibrinolysis required before use

›Activated protein C (drotrecogin alfa) — withdrawn; increased bleeding without mortality benefit

11Patient Discharge Instructions/pdi34

copy discharge instructions

›Understanding your diagnosis

›Disseminated intravascular coagulation (DIC) is a serious blood clotting disorder caused by another medical condition

›It is not a disease by itself — the underlying cause has been treated

›Your blood tests should continue to improve as you recover

›Signs to return to the emergency department immediately

›New or worsening bleeding

›Unexpected bruising, bleeding from gums, nose, or wounds

›Blood in urine (red or dark brown color) or blood in stool (black tarry stools)

›Heavy vaginal bleeding (if recently pregnant)

›Signs of infection

›Fever above 38.3 C

›Chills, shaking, or feeling very unwell

›Neurologic changes

›Sudden confusion, weakness, or difficulty speaking

›Severe headache

›Breathing difficulty

›Shortness of breath at rest or chest pain

›Decreased urine output or no urine for more than 8 hours

›Skin color changes

›New purple or black patches on skin

›Fingers or toes becoming dark, cold, or painful

›Follow-up instructions

›Repeat blood tests

›CBC and coagulation panel within 1 to 2 weeks of discharge

›Earlier if any new symptoms

›Specialist follow-up

›Hematology follow-up if malignancy-associated or complex coagulopathy

12References/r30

Guidelines and key sources

›ISTH SSC 2025 DIC Definition Update

›Iba T, Levy JH, Maier CL, et al. Updated Definition and Scoring of Disseminated Intravascular Coagulation in 2025

›Journal of Thrombosis and Haemostasis 2025

›PMID 40216223

›Introduces phase-based classification and updated D-dimer thresholds (> 3x and > 7x ULN)

›Levi M, Scully M. How I Treat Disseminated Intravascular Coagulation

›Blood 2018; PMID 29255070

›Comprehensive treatment framework including blood product replacement thresholds

›Hunt BJ. Bleeding and Coagulopathies in Critical Care

›New England Journal of Medicine 2014

›Evidence-based review of FFP, cryoprecipitate, and platelet thresholds

›Wada H, Thachil J, Di Nisio M, et al. Guidance for Diagnosis and Treatment of DIC

›Journal of Thrombosis and Haemostasis 2013; PMID 23379279

›Harmonization of ISTH, BCSH, and JSTH DIC guidelines

›Gando S, Levi M, Toh CH. Disseminated Intravascular Coagulation

›Nature Reviews Disease Primers 2016; PMID 27250996

›Pathophysiology, epidemiology, and classification

Clinical scoring and prognosis

›Iba T, Levi M, Thachil J, et al. Sepsis-Induced Coagulopathy Management

›Journal of Thrombosis and Haemostasis 2023; PMID 36695377

›SIC score validation and management recommendations

›SIC score >= 4 identifies early DIC in approximately 60% of sepsis patients

›Iba T, Maier CL, Tanigawa T, Levy JH. Risk Stratification in Sepsis-Associated DIC

›Scientific Reports 2023; PMID 38110515

›Antithrombin < 47% and SOFA >= 12 predict > 40% 28-day mortality

›Wada T, et al. DIC Resolution as Surrogate Outcome for Mortality

›Thrombosis Research 2025; PMID 40997637

Learn More: Disseminated Intravascular Coagulation (DIC)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.